Sax Wealth Advisors LLC Purchases New Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Sax Wealth Advisors LLC acquired a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the 2nd quarter, HoldingsChannel reports. The fund acquired 17,735 shares of the company’s stock, valued at approximately $288,000.

Several other large investors also recently made changes to their positions in TEVA. Edmond DE Rothschild Holding S.A. raised its holdings in shares of Teva Pharmaceutical Industries by 4.0% during the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 24,495 shares of the company’s stock valued at $346,000 after buying an additional 947 shares during the period. Desjardins Global Asset Management Inc. raised its stake in shares of Teva Pharmaceutical Industries by 15.2% during the fourth quarter. Desjardins Global Asset Management Inc. now owns 8,123 shares of the company’s stock valued at $85,000 after purchasing an additional 1,070 shares during the period. Oppenheimer & Co. Inc. lifted its position in shares of Teva Pharmaceutical Industries by 9.6% during the first quarter. Oppenheimer & Co. Inc. now owns 13,522 shares of the company’s stock worth $191,000 after purchasing an additional 1,180 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its stake in shares of Teva Pharmaceutical Industries by 2.1% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 67,996 shares of the company’s stock valued at $688,000 after purchasing an additional 1,375 shares during the period. Finally, Transcend Capital Advisors LLC grew its holdings in Teva Pharmaceutical Industries by 13.6% during the 4th quarter. Transcend Capital Advisors LLC now owns 12,543 shares of the company’s stock valued at $131,000 after purchasing an additional 1,500 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Piper Sandler reiterated an “overweight” rating and issued a $20.00 price objective (up previously from $19.00) on shares of Teva Pharmaceutical Industries in a report on Monday, May 13th. UBS Group increased their price target on Teva Pharmaceutical Industries from $22.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, July 10th. Jefferies Financial Group lifted their price objective on Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Argus upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research note on Wednesday, July 10th. Finally, Barclays raised their price target on shares of Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and a consensus target price of $18.67.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock traded up $0.27 on Friday, hitting $17.43. 7,333,549 shares of the stock traded hands, compared to its average volume of 10,408,303. The company has a market capitalization of $19.74 billion, a PE ratio of -42.51, a PEG ratio of 1.47 and a beta of 0.90. The company’s fifty day moving average is $16.82 and its 200 day moving average is $14.91. The company has a debt-to-equity ratio of 2.52, a current ratio of 0.89 and a quick ratio of 0.59. Teva Pharmaceutical Industries Limited has a 1-year low of $8.06 and a 1-year high of $18.02.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, May 8th. The company reported $0.46 earnings per share for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.03). Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. The business had revenue of $3.82 billion for the quarter, compared to analyst estimates of $3.70 billion. On average, equities research analysts predict that Teva Pharmaceutical Industries Limited will post 2.35 earnings per share for the current fiscal year.

Insider Activity at Teva Pharmaceutical Industries

In other news, insider Vikki L. Conway sold 15,219 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $16.74, for a total transaction of $254,766.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Roberto Mignone sold 519,000 shares of the stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $17.03, for a total value of $8,838,570.00. Following the sale, the director now owns 981,000 shares of the company’s stock, valued at approximately $16,706,430. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Vikki L. Conway sold 15,219 shares of the business’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $16.74, for a total transaction of $254,766.06. The disclosure for this sale can be found here. Insiders sold a total of 574,256 shares of company stock valued at $9,776,999 in the last quarter. Insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.